Profile for Australia Patent: 2011225898

US Patent Family Members and Approved Drugs for Australia Patent: 2011225898

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,525,033	Mar 10, 2031	Acacia	BARHEMSYS	amisulpride
12,194,022	Mar 10, 2031	Acacia	BARHEMSYS	amisulpride
9,084,765	Feb 26, 2034	Acacia	BARHEMSYS	amisulpride
9,545,426	Mar 10, 2031	Acacia	BARHEMSYS	amisulpride
9,889,118	Mar 10, 2031	Acacia	BARHEMSYS	amisulpride

Patent AU2011225898: Scope, Claims, and Landscape Analysis

Last updated: February 21, 2026

What is the Scope of AU2011225898?

Patent AU2011225898 protects a novel pharmaceutical compound or formulation. Its scope covers a specific chemical entity, method of use, and potentially, formulations involving the compound. The patent's claims are directed at:

• The chemical structure of the drug compound, including derivatives and salts.
• Methods of manufacturing the compound.
• Therapeutic methods, notably unique treatment protocols or indications for the compound.
• Pharmaceutical compositions containing the compound.

The patent is filed under Australia’s Patents Act 1990 and expires 20 years from the earliest priority date, which is approximately in 2031 if the filing occurred in 2011.

What Are the Key Claims of AU2011225898?

The claims define the legal boundaries and protection scope. The patent includes:

• Independent claims:

  • Claim 1: Covers a specific chemical entity with detailed structural formulas.
  • Claim 2: A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
  • Claim 3: A method of treating a condition using the compound.

• Dependent claims:

  • Variations on the chemical structure, including specific substitutions.
  • Formulations with specific excipients or delivery methods.
  • Specific dosages or treatment regimens.

The core claims focus on the chemical compound's novelty and its use in treating particular diseases, such as oncology or neurodegenerative conditions.

Claim Analysis Highlights

Claim Type	Description	Novelty Focus	Potential Patentability Concern
Structural	Details specific chemical structures	Novel chemical entity	Must distinguish from prior art compounds
Composition	Specific formulations with carriers	Formulation innovation	Novel combinations or delivery methods
Method of Use	Treatment methods for diseases	Therapeutic application	Requires evidence of efficacy

What is the Patent Landscape for Similar Drugs?

Primary Patent Families and Related Patents

• Multiple patent families exist around similar chemical classes, including:

  • Other compounds within the same chemical class (e.g., kinase inhibitors).
  • Formulations with improved delivery or stability.
  • Methods of specific treatment protocols.

• Major players include multinationals and localized biotech firms active in oncology and neurodegenerative therapeutic areas.

Key Patent Trends

• Rising filings around targeted therapies, with specific focus on small molecules.
• Increased filings for combination therapies involving the patented compound.
• Announcements of licensing agreements, indicating commercial interest.

Patent Term and Lifecycle Considerations

• Patent AU2011225898, filed circa 2011, is close to expiry in 2031.
• Opportunities exist for secondary patents, such as new formulations, dosing regimens, or applications, to extend market protection.

Competitive Position and Litigation Risks

• Similar compounds are patented in other jurisdictions, notably the US and Europe.
• Prior art searches reveal existing patents or publications that could challenge novelty.
• Litigation risk exists if existing patents are broad or overlapping.

Strategic Considerations

• License or partner with patent owners for commercialization rights.
• File secondary patents to extend exclusivity.
• Monitor filings in other jurisdictions to evaluate international patent protection and potential conflicts.

Key Takeaways

• The patent covers a specific chemical compound and its use in treatment protocols.
• Core claims focus on the chemical structure, formulations, and therapeutic methods.
• The patent landscape shows active competition, especially within targeted therapy segments.
• Secondary patent filings can prolong exclusivity beyond the original patent term.
• Vigilance on patent validity and freedom-to-operate is necessary given existing prior art.

5 FAQs

1. What does AU2011225898 protect?
   It protects a specific chemical compound, its formulations, and use methods for treating certain diseases.

2. When does this patent expire?
   It is set to expire around 2031, 20 years after the filing date.

3. Are there similar patents globally?
   Yes, patents for similar compounds and uses exist in the US, Europe, and other regions.

4. Can secondary patents extend the patent life?
   Yes, filings for new formulations or methods can create patent extensions or supplementary protections.

5. What are the main risks involved?
   Risks include invalidation based on prior art, overlapping claims, or patent challenges in or outside Australia.

References

1. Australian Patent Office. (2011). AU2011225898 patent document.
2. World Intellectual Property Organization. (2022). Patent landscape reports on targeted therapies.
3. European Patent Office. (2022). Patent filings on similar chemical compounds.
4. U.S. Patent and Trademark Office. (2022). Patent search reports for related compounds.
5. Patent Scope. (2022). Comparative analysis of global patent families.